RxDoctor Payments Data

Elizabeth Webster, MD

General Practice · Hayes, VANPI 1295936763

Payments from drug & device makers

$1,431in general payments, 2019–2025

Across 28 payments — averaging $51.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Products, LP$285
  • Viiv Healthcare Company$249
  • GSK$243
  • Gilead$192
  • AstraZeneca$125
  • Novo Nordisk$122
  • plus $216 from 6 others

What the payments were for

  • Food & beverage$1,11878%
  • Education$31322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,431 in reported general payments places this provider in the 85th percentile of 2,591 general practice providers in Virginia.

See all general practice providers in Virginia

Medicare billing

Part B allowed, 2024
$176
Medicare patients
15
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala26$104,857
JardianceEmpagliflozin135$103,296
TrulicityDulaglutide59$70,453
EliquisApixaban55$47,094
TriumeqAbacavir/Dolutegravir/Lamivudi11$38,749
EntrestoSacubitril/Valsartan29$19,453
Janumet XrSitagliptin Phos/Metformin Hcl45$17,823
Soliqua 100-33Insulin Glargine/Lixisenatide14$14,810
XareltoRivaroxaban14$14,375
FarxigaDapagliflozin Propanediol15$13,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,438
Humalog Kwikpen U-100Insulin Lispro15$6,342
Spiriva HandihalerTiotropium Bromide12$6,335
Albuterol Sulfate HfaAlbuterol Sulfate133$5,305
Incruse ElliptaUmeclidinium Bromide12$4,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$192$104,85726 claims
Viiv Healthcare CompanyTriumeq$249$38,74911 claims
MerckJanumet Xr$14$17,82345 claims
GSKTrelegy Ellipta, Incruse Ellipta$243$15,61626 claims
Johnson & JohnsonXarelto$108$14,37514 claims
AstraZenecaFarxiga$125$13,86915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,591 general practice providers in Virginia.

Other general practice in Hayes

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →